3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Autor:	Iveson, Timothy J1 (AUTHOR), Kerr, Rachel S2 (AUTHOR), Saunders, Mark P3 (AUTHOR), Cassidy, Jim4 (AUTHOR), Hollander, Niels Henrik5 (AUTHOR), Tabernero, Josep6 (AUTHOR), Haydon, Andrew7 (AUTHOR), Glimelius, Bengt8 (AUTHOR), Harkin, Andrea4 (AUTHOR), Allan, Karen4 (AUTHOR), McQueen, John4 (AUTHOR), Scudder, Claire9 (AUTHOR), Boyd, Kathleen Anne10 (AUTHOR), Briggs, Andrew11 (AUTHOR), Waterston, Ashita12 (AUTHOR), Medley, Louise13 (AUTHOR), Wilson, Charles14 (AUTHOR), Ellis, Richard15 (AUTHOR), Essapen, Sharadah16 (AUTHOR), Dhadda, Amandeep S17 (AUTHOR)
Zdroj:	Lancet Oncology. Apr2018, Vol. 19 Issue 4, p562-578. 17p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu